Is DNA or ASRT more profitable?

Assertio has a net margin of -34.94% compared to Ginkgo Bioworks' net margin of -215.41%. Assertio's return on equity of -38.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% Assertio -34.94% -38.72% -13.32%

Which has stronger earnings and valuation, ASRT or ALT?

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A Altimmune $40K 14,342.16 -$88.09M -$0.93 N/A

Is ASRT or ALT more profitable?

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Assertio -34.94% -38.72% -13.32% Altimmune -214,860.98% -42.57% -35.57%

Does the media prefer ASRT or ALT?

In the previous week, Altimmune had 2 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Altimmune and 1 mentions for Assertio. Altimmune's average media sentiment score of 0.55 beat Assertio's score of 0.00 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TECX or ASRT?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 1 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ASRT or AVTE?

Assertio presently has a consensus price target of $22.65, suggesting a potential downside of 3.62%. Given Assertio's stronger consensus rating and higher possible upside, equities analysts plainly believe Assertio is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Assertio (ASRT) Competitors

$23.50 0.00 (0.00%)

As of 06/17/2026

Compare

ASRT vs. GYRE, DNA, ALT, TECX, and AVTE

Should you buy Assertio stock or one of its competitors? MarketBeat compares Assertio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assertio include Gyre Therapeutics (GYRE), Ginkgo Bioworks (DNA), Altimmune (ALT), Tectonic Therapeutic (TECX), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Assertio compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Assertio had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Assertio and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Assertio	Neutral

Gyre Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 162.35%. Assertio has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gyre Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gyre Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Assertio has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Gyre Therapeutics has a net margin of -5.44% compared to Assertio's net margin of -34.94%. Gyre Therapeutics' return on equity of 3.13% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Assertio	-34.94%	-38.72%	-13.32%

Gyre Therapeutics has higher earnings, but lower revenue than Assertio. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Summary

Gyre Therapeutics beats Assertio on 11 of the 15 factors compared between the two stocks.

How does Assertio compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Assertio has a net margin of -34.94% compared to Ginkgo Bioworks' net margin of -215.41%. Assertio's return on equity of -38.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Assertio	-34.94%	-38.72%	-13.32%

Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Assertio has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Assertio has lower revenue, but higher earnings than Ginkgo Bioworks. Assertio is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.72	-$312.76M	-$5.36	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Ginkgo Bioworks currently has a consensus target price of $8.50, indicating a potential downside of 12.40%. Assertio has a consensus target price of $22.65, indicating a potential downside of 3.62%. Given Assertio's stronger consensus rating and higher possible upside, analysts plainly believe Assertio is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Assertio had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 1 mentions for Assertio and 0 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Assertio	Neutral

Summary

Ginkgo Bioworks beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Assertio compare to Altimmune?

Assertio (NASDAQ:ASRT) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Altimmune	-214,860.98%	-42.57%	-35.57%

Assertio presently has a consensus price target of $22.65, suggesting a potential downside of 3.62%. Altimmune has a consensus price target of $15.71, suggesting a potential upside of 432.69%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Altimmune	$40K	14,342.16	-$88.09M	-$0.93	N/A

In the previous week, Altimmune had 2 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Altimmune and 1 mentions for Assertio. Altimmune's average media sentiment score of 0.55 beat Assertio's score of 0.00 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

49.0% of Assertio shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 5.7% of Assertio shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Assertio has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Summary

Altimmune beats Assertio on 9 of the 16 factors compared between the two stocks.

How does Assertio compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Tectonic Therapeutic has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Tectonic Therapeutic's return on equity of -32.33% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Assertio	-34.94%	-38.72%	-13.32%

Tectonic Therapeutic has a beta of 3.19, meaning that its stock price is 219% more volatile than the broader market. Comparatively, Assertio has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 5.7% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 1 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Assertio has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Tectonic Therapeutic presently has a consensus target price of $79.40, suggesting a potential upside of 158.46%. Assertio has a consensus target price of $22.65, suggesting a potential downside of 3.62%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts plainly believe Tectonic Therapeutic is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Tectonic Therapeutic beats Assertio on 10 of the 14 factors compared between the two stocks.

How does Assertio compare to Aerovate Therapeutics?

Assertio (NASDAQ:ASRT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Assertio has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Aerovate Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

49.0% of Assertio shares are held by institutional investors. 5.7% of Assertio shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Assertio presently has a consensus price target of $22.65, suggesting a potential downside of 3.62%. Given Assertio's stronger consensus rating and higher possible upside, equities analysts plainly believe Assertio is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Assertio had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Assertio and 0 mentions for Aerovate Therapeutics. Assertio's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Assertio	Neutral
Aerovate Therapeutics	Neutral

Summary

Assertio beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Assertio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASRT vs. The Competition

Export

Metric	Assertio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151.81M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-4.13	18.65	25.14	23.95
Price / Sales	1.28	341.96	531.12	107.90
Price / Cash	1,437.29	56.64	45.29	53.76
Price / Book	1.61	4.14	10.77	6.41
Net Income	-$30.38M	$64.45M	$3.56B	$337.14M
7 Day Performance	N/A	1.22%	1.00%	-1.06%
1 Month Performance	0.26%	0.95%	0.81%	0.49%
1 Year Performance	148.13%	25.22%	30.27%	28.43%

Assertio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASRT Assertio	1.1843 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20
GYRE Gyre Therapeutics	2.0709 of 5 stars	$6.11 -0.4%	$17.00 +178.5%	-14.8%	$596.92M	$117.05M	N/A	40	Positive News
DNA Ginkgo Bioworks	0.1641 of 5 stars	$8.96 -0.9%	$8.50 -5.1%	+5.8%	$586.90M	$170.15M	N/A	640	Gap Up
ALT Altimmune	2.0773 of 5 stars	$3.02 +2.9%	$15.71 +421.2%	-59.0%	$584.38M	$40K	N/A	50	Analyst Forecast Options Volume
TECX Tectonic Therapeutic	2.4625 of 5 stars	$30.84 +1.6%	$79.40 +157.5%	+52.3%	$583.99M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASRT) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assertio (ASRT) Competitors

ASRT vs. GYRE, DNA, ALT, TECX, and AVTE

How does Assertio compare to Gyre Therapeutics?

Summary

How does Assertio compare to Ginkgo Bioworks?

Summary

How does Assertio compare to Altimmune?

Summary

How does Assertio compare to Tectonic Therapeutic?

Summary

How does Assertio compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assertio (ASRT) Competitors

ASRT vs. GYRE, DNA, ALT, TECX, and AVTE

How does Assertio compare to Gyre Therapeutics?

Does the media favor GYRE or ASRT?

Do analysts recommend GYRE or ASRT?

Do insiders & institutionals hold more shares of GYRE or ASRT?

Which has more risk & volatility, GYRE or ASRT?

Is GYRE or ASRT more profitable?

Which has better valuation and earnings, GYRE or ASRT?

Summary

How does Assertio compare to Ginkgo Bioworks?

Is DNA or ASRT more profitable?

Which has more volatility & risk, DNA or ASRT?

Do insiders and institutionals hold more shares of DNA or ASRT?

Which has higher earnings & valuation, DNA or ASRT?

Do analysts recommend DNA or ASRT?

Does the media refer more to DNA or ASRT?

Summary

How does Assertio compare to Altimmune?

Is ASRT or ALT more profitable?

Do analysts prefer ASRT or ALT?

Which has stronger earnings and valuation, ASRT or ALT?

Does the media prefer ASRT or ALT?

Do insiders & institutionals have more ownership in ASRT or ALT?

Which has more volatility & risk, ASRT or ALT?

Summary

How does Assertio compare to Tectonic Therapeutic?

Is TECX or ASRT more profitable?

Which has more risk & volatility, TECX or ASRT?

Do institutionals and insiders hold more shares of TECX or ASRT?

Does the media favor TECX or ASRT?

Which has higher earnings and valuation, TECX or ASRT?

Do analysts recommend TECX or ASRT?

Summary

How does Assertio compare to Aerovate Therapeutics?

Which has higher earnings and valuation, ASRT or AVTE?

Is ASRT or AVTE more profitable?

Which has more risk and volatility, ASRT or AVTE?

Do institutionals & insiders have more ownership in ASRT or AVTE?

Do analysts recommend ASRT or AVTE?

Does the media refer more to ASRT or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools